Cargando…
Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials
OBJECTIVE: To evaluate the efficacy and safety of roxadustat in the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. MATERIALS AND METHODS: For this systematic review and meta-analysis, we searched for randomized controlled trials (RCTs) of anemia in NDD-CKD p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710737/ https://www.ncbi.nlm.nih.gov/pubmed/36466382 http://dx.doi.org/10.3389/fnut.2022.1029432 |
_version_ | 1784841429625864192 |
---|---|
author | Chen, Ting Huang, Junyue Dong, Hui Xu, Lili Chen, Caihe Tang, Yu Huang, Wenhui |
author_facet | Chen, Ting Huang, Junyue Dong, Hui Xu, Lili Chen, Caihe Tang, Yu Huang, Wenhui |
author_sort | Chen, Ting |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of roxadustat in the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. MATERIALS AND METHODS: For this systematic review and meta-analysis, we searched for randomized controlled trials (RCTs) of anemia in NDD-CKD patients to assess the efficacy and safety of roxadustat. The primary efficacy endpoint was the proportion of patients who achieved a hemoglobin (Hb) response. Secondary efficacy endpoints were hepcidin, serum iron, serum ferritin (SF), total iron-binding capacity (TIBC), transferrin saturation (TAST), and low-density lipoprotein (LDL). In addition, adverse events (AEs) were compared. Meta-analyses were performed using Revman 5.4 software. The quality of the evidence was assessed using the Cochrane risk of bias tool. This study was conducted under a pre-established protocol registered with PROSPERO (registration number: CRD42021252331). RESULTS: Seven studies enrolled 4,764 patients, of whom 2,730 received roxadustat and 2,034 received placebo. The results of this meta-analysis showed that roxadustat increased Hb levels [weighted mean difference (WMD) = 1.43, 95% CI: 1.17 to 1.68, P < 0.001, I(2) = 95%], and Hb response [relative ratio (RR) = 8.12, 95% CI: 5.80 to 11.37, P < 0.001, I(2) = 61%]. In addition, roxadustat significantly increased transferrin TAST. During the treatment period in patients with anemia, the AEs of roxadustat compared with placebo was not statistically significant. CONCLUSION: Roxadustat can improve anemia in NDD-CKD patients by increasing Hb levels and regulating iron metabolism, but does not increase the incidence of AEs. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021252331]. |
format | Online Article Text |
id | pubmed-9710737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97107372022-12-01 Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials Chen, Ting Huang, Junyue Dong, Hui Xu, Lili Chen, Caihe Tang, Yu Huang, Wenhui Front Nutr Nutrition OBJECTIVE: To evaluate the efficacy and safety of roxadustat in the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. MATERIALS AND METHODS: For this systematic review and meta-analysis, we searched for randomized controlled trials (RCTs) of anemia in NDD-CKD patients to assess the efficacy and safety of roxadustat. The primary efficacy endpoint was the proportion of patients who achieved a hemoglobin (Hb) response. Secondary efficacy endpoints were hepcidin, serum iron, serum ferritin (SF), total iron-binding capacity (TIBC), transferrin saturation (TAST), and low-density lipoprotein (LDL). In addition, adverse events (AEs) were compared. Meta-analyses were performed using Revman 5.4 software. The quality of the evidence was assessed using the Cochrane risk of bias tool. This study was conducted under a pre-established protocol registered with PROSPERO (registration number: CRD42021252331). RESULTS: Seven studies enrolled 4,764 patients, of whom 2,730 received roxadustat and 2,034 received placebo. The results of this meta-analysis showed that roxadustat increased Hb levels [weighted mean difference (WMD) = 1.43, 95% CI: 1.17 to 1.68, P < 0.001, I(2) = 95%], and Hb response [relative ratio (RR) = 8.12, 95% CI: 5.80 to 11.37, P < 0.001, I(2) = 61%]. In addition, roxadustat significantly increased transferrin TAST. During the treatment period in patients with anemia, the AEs of roxadustat compared with placebo was not statistically significant. CONCLUSION: Roxadustat can improve anemia in NDD-CKD patients by increasing Hb levels and regulating iron metabolism, but does not increase the incidence of AEs. SYSTEMATIC REVIEW REGISTRATION: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021252331]. Frontiers Media S.A. 2022-11-04 /pmc/articles/PMC9710737/ /pubmed/36466382 http://dx.doi.org/10.3389/fnut.2022.1029432 Text en Copyright © 2022 Chen, Huang, Dong, Xu, Chen, Tang and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Chen, Ting Huang, Junyue Dong, Hui Xu, Lili Chen, Caihe Tang, Yu Huang, Wenhui Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title | Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title_full | Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title_fullStr | Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title_full_unstemmed | Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title_short | Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials |
title_sort | efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: a systematic review and meta-analysis of randomized double-blind controlled clinical trials |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710737/ https://www.ncbi.nlm.nih.gov/pubmed/36466382 http://dx.doi.org/10.3389/fnut.2022.1029432 |
work_keys_str_mv | AT chenting efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT huangjunyue efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT donghui efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT xulili efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT chencaihe efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT tangyu efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials AT huangwenhui efficacyandsafetyofroxadustatforthetreatmentofanemiainnondialysischronickidneydiseasepatientsasystematicreviewandmetaanalysisofrandomizeddoubleblindcontrolledclinicaltrials |